The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Biologic agents for IBD: practical insights
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Self-citationManagement of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Sandborn, W. J., Gasink, C., Gao, L.-L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203572 · Cited by 1,134
Greenfield, S., Kaplan, S. H., Ware, J. E., Yano, E. M., & Frank, H. J. L. (1988) · Journal of General Internal Medicine · doi:10.1007/bf02595921 · Cited by 1,119
Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Panaccione, R., Ghosh, S., Middleton, S., Márquez, J. R., Scott, B. B., Flint, L., van Hoogstraten, H. J. F., Chen, A. C., Zheng, H., Danese, S., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.10.052 · Cited by 963
Self-citationVan Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
Reinisch, W., Sandborn, W. J., Hommes, D. W., D'Haens, G., Hanauer, S., Schreiber, S., Panaccione, R., Fedorak, R. N., Tighe, M. B., Huang, B., et al. (2011) · Gut · doi:10.1136/gut.2010.221127 · Cited by 892
Robinson, R. (1993) · BMJ · doi:10.1136/bmj.307.6907.793 · Cited by 816
A meta-analysis of randomized controlled trials: Efficacy of selenium treatment for sepsis
Li, S., Tang, T., Guo, P., Zou, Q., Ao, X., Hu, L., & Tan, L. (2019) · Medicine · doi:10.1097/md.0000000000014733 · Cited by 802
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Nachury, M., Moreau, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61084-8 · Cited by 646
Vermeire, S., Noman, M., Van Assche, G., Baert, F., D’Haens, G., & Rutgeerts, P. (2007) · Gut · doi:10.1136/gut.2006.099978 · Cited by 602
Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J., & Sands, B. E. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.01.004 · Cited by 511
van der Valk, M. E., Mangen, M.-J. J., Leenders, M., Dijkstra, G., van Bodegraven, A. A., Fidder, H. H., de Jong, D. J., Pierik, M., van der Woude, C. J., Romberg-Camps, M. J. L., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-303376 · Cited by 500
Karmiris, K., Paintaud, G., Noman, M., Magdelaine–Beuzelin, C., Ferrante, M., Degenne, D., Claes, K., Coopman, T., Van Schuerbeek, N., Van Assche, G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.062 · Cited by 478
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Vermeire, S., O'Byrne, S., Keir, M., Williams, M., Lu, T. T., Mansfield, J. C., Lamb, C. A., Feagan, B. G., Panes, J., Salas, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60661-9 · Cited by 452
Ford, A. C., & Peyrin-Biroulet, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.138 · Cited by 343
Self-citationNanda, K. S., Cheifetz, A. S., & Moss, A. C. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.363 · Cited by 336
Gisbert, J. P., Marín, A. C., McNicholl, A. G., & Chaparro, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13083 · Cited by 323
Ko, J. M., Gottlieb, A. B., & Kerbleski, J. F. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 313
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Anzengruber, F., Maul, J.-T., Kamarachev, J., Trüeb, R. M., French, L. E., & Navarini, A. A. (2016) · Case Reports in Dermatology · doi:10.1159/000445182 · Cited by 304
Nikolakopoulou, A., White, I. R., & Salanti, G. (2020) · Handbook of Meta-Analysis · doi:10.1201/9781315119403-10 · Cited by 303
Tillack, C., Ehmann, L. M., Friedrich, M., Laubender, R. P., Papay, P., Vogelsang, H., Stallhofer, J., Beigel, F., Bedynek, A., Wetzke, M., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-302853 · Cited by 302
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Wang, W., Niezychowski, W., Vermeire, S. A. R. A., Dewit, O., Peeters, H., Stehlik, J., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.029 · Cited by 300
Hazlewood, G. S., Rezaie, A., Borman, M., Panaccione, R., Ghosh, S., Seow, C. H., Kuenzig, E., Tomlinson, G., Siegel, C. A., Melmed, G. Y., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.011 · Cited by 276
Gibson, D. J., Heetun, Z. S., Redmond, C. E., Nanda, K. S., Keegan, D., Byrne, K., Mulcahy, H. E., Cullen, G., & Doherty, G. A. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.041 · Cited by 268
Patient participation in deciding breast cancer treatment and subsequent quality of life
Street, R. L., & Voigt, B. (1997) · Medical Decision Making · doi:10.1177/0272989x9701700306 · Cited by 258
Odes, S., Vardi, H., Friger, M., Wolters, F., Russel, M. G., Riis, L., Munkholm, P., Politi, P., Tsianos, E., Clofent, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.052 · Cited by 224
Singh, S., Nagpal, S. J. S., Murad, M. H., Yadav, S., Kane, S. V., Pardi, D. S., Talwalkar, J. A., & Loftus, E. V. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.033 · Cited by 210
Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies
Reinisch, W., Sandborn, W. J., Rutgeerts, P., Feagan, B. G., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., de Villiers, W. J. S., Blank, M., Lang, Y., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21697 · Cited by 208
Stidham, R. W., Lee, T. C. H., Higgins, P. D. R., Deshpande, A. R., Sussman, D. A., Singal, A. G., Elmunzer, B. J., Saini, S. D., Vijan, S., & Waljee, A. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12749 · Cited by 201
Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L., & Bonovas, S. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2403 · Cited by 195
Self-citationWilliams, C. J. M., Peyrin‐Biroulet, L., & Ford, A. C. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12624 · Cited by 171
Self-citationRahier, J., Buche, S., Peyrin–Biroulet, L., Bouhnik, Y., Duclos, B., Louis, E., Papay, P., Allez, M., Cosnes, J., Cortot, A., et al. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.07.022 · Cited by 166
Self-citationStidham, R. W., Lee, T. C. H., Higgins, P. D. R., Deshpande, A. R., Sussman, D. A., Singal, A. G., Elmunzer, B. J., Saini, S. D., Vijan, S., & Waljee, A. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12644 · Cited by 159
Assche, G. V., Vermeire, S., Ballet, V., Gabriels, F., Noman, M., D’Haens, G., Claessens, C., Humblet, E. H., Casteele, N. V., Gils, A., et al. (2011) · Gut · doi:10.1136/gutjnl-2011-300755 · Cited by 139
Dretzke, J., Edlin, R. P., Round, J. A., Connock, M. J., Hulme, C. T., Czeczot, J., Fry-Smith, A., McCabe, C. J., & Meads, C. (2011) · Health Technology Assessment · doi:10.3310/hta15060 · Cited by 134
Colombel, J., Sandborn, W. J., Allez, M., Dupas, J., Dewit, O., D’Haens, G., Bouhnik, Y., Parker, G., Pierre‐Louis, B. J., & Hébuterne, X. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.10.025 · Cited by 129
Bodger, K., KIKUCHI, T., & Hughes, D. A. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04033.x · Cited by 124
Dulai, P. S., Siegel, C. A., Colombel, J., Sandborn, W. J., & Peyrin‐Biroulet, L. (2014) · Gut · doi:10.1136/gutjnl-2014-307126 · Cited by 112
Self-citationLichtenstein, G. R., Thomsen, O. Ø., Schreiber, S., Lawrance, I. C., Hanauer, S. B., Bloomfield, R., & Sandborn, W. J. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.01.014 · Cited by 109
Danese, S., & Panés, J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.044 · Cited by 98
Self-citationLong-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
Parikh, A., Fox, I. H., Leach, T. S., Xu, J., Scholz, C. R., Patella, M., & Feagan, B. G. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f538 · Cited by 80
Singh, S., Garg, S. K., Pardi, D. S., Wang, Z., Murad, M. H., & Loftus, E. V. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.08.019 · Cited by 71
Vavricka, S. R., Bentele, N., Scharl, M. M., Rogler, G., Zeitz, J., Frei, P., Straumann, A., Binek, J., Schoepfer, A. M., & Fried, M. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21888 · Cited by 70
Rodgers, M., Soares, M. O., Epstein, D. M., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15suppl1-01 · Cited by 67
Patient preferences in choosing anti-TNF therapies-R1
Williams, E. L., & Edwards, C. J. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel369 · Cited by 58
Introducing Vedolizumab to Clinical Practice: Who, When, and How?
Bryant, R. V., Sandborn, W., & Travis, S. P. L. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv033 · Cited by 56
Feagan, B. G., Sandborn, W. J., Lichtenstein, G. R., Radford‐Smith, G. L., PATEL, J., & Innes, A. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02791.x · Cited by 44
Hayes, M., Stein, A. C., & Sakuraba, A. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12517 · Cited by 33
Cost‐Utility Analysis of Biologic Treatments for Moderate‐to‐Severe Crohn's Disease
Tang, D. H., Armstrong, E. P., & Lee, J. K. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01053.x · Cited by 32
Economic Implications of Biological Therapies for Crohn???s Disease: Review of Infliximab
Bodger, K. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523090-00002 · Cited by 28
Long-term outcome of IBD patients with primary non-response to anti-TNF therapy
Papamichael, K., Rivals-Lerebours, O., Billiet, T., Ferrante, M., Assche, G. V., Rutgeerts, P., Mantzaris, G. J., Peyrin‐Biroulet, L., & Vermeire, S. (2015) · Journal of Crohns & Colitis · Cited by 6
Self-citationEffects on Blood Sugar Control and Quality of Life in Diabetes
Greenfield, S., Kaplan, S. H., Yano, E. M., & Frank, H. J. L. (1988) · Cited by 6
Cited by
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Self-citationBonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G. K., Peyrin-Biroulet, L., & Danese, S. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.039 · Cited by 387
Self-citationSingh, S., Murad, M. H., Fumery, M., Dulai, P. S., & Sandborn, W. J. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.008 · Cited by 375
Olivera, P. A., Lasa, J. S., Bonovas, S., Danese, S., & Peyrin-Biroulet, L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.001 · Cited by 330
Self-citationThe metabolic nature of inflammatory bowel diseases
Adolph, T. E., Meyer, M., Schwärzler, J., Mayr, L., Grabherr, F., & Tilg, H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00658-y · Cited by 296
Metadata
- Authors
- Danese, S., Vuitton, L., & Peyrin-Biroulet, L.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2015-08-18
- Volume
- 12
- Issue
- 9
- Pages
- 537-545
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W2198790708
- Cited by
- 342
- References
- 65
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.